Fig. 2

FABP4 on CD11b and angiogenesis and their regulation by Semaglutide. A Dot plots or histogram of CD11b expression levels, expressed by relative fluorescence units (RFU) and analyzed by flow cytometry, after FABP4 (6.8 nM) with or without semaglutide (Sema) 1 nM for 90 min on neutrophil-like dHL-60 cells. Bar graph with individual data points represents the CD11b levels after treatments. Statistical analysis shows an increase of CD11b after FABP4 treatment and modulated by semaglutide cotreatment (1 nM) [n = 6; one-way ANOVA, F(2,5) = 18.72, p = 0.0017; p < 0.01; Tukey’s post-hoc Control (539.8 ± 51.41) vs FABP4 (574.3 ± 53.41), adjusted p value = 0.0071; p < 0.001; Tukey’s post-hoc FABP4 (574.3 ± 53.41) vs Sema + FABP4 (550.3 ± 44), adjusted p value = 0.0345; p < 0.05]. B Representative fluorescence microscopy images of human aortic endothelial cells (HAEC) after treatments (semaglutide (1 nM), FABP4 (6.8 nM) or both) for 20 h on an angiogenesis assay (HAEC are shown in green. Scale bar = 100 μm). Bar graphs with individual data points represents the mesh number, mesh % over total area and total mesh area. Statistical analysis shows an angiogenesis effect of cotreatment based on number of meshes [n = 12; Friedman test, p = 0.043; p < 0.05; Dunn`s multiple comparisons test: Vehicle (Veh) (8.167 ± 3.738) vs Sema + FABP4 (14.25 ± 4.372), adjusted p value = 0.0339; p < 0.05] and total mesh area [n = 12 one-way ANOVA, F(3,11) = 3.049, p = 0.0064; p < 0.01; Tukey’s post-hoc Veh (557229 ± 293903) vs Sema + FABP4 (853809 ± 157386), adjusted p value = 0.0353; p < 0.05]